1PostemaPTE,KrenningEP,WijingaardeR ,etal.lllIn DTPA D Phe’’]octreotidescintigraphyinthyroidalandorbitalGra ves’’disease:aparameterfordiseaseactivity〔J〕[].JClinEndo crinolMetab.1994
2Kahaly G,Hansen C,Beyer J,et al.Plasma glycosaminoglycans in endocrine ophthalmopathy〔J〕[].Journal of Endocrinological Investigation.1994
3Kahaly G,Forster G,Hansen C.Glycosaminoglycans in thyroid eye disease〔J〕[].Thyroid.1998
4Pappa A,Jackson P,Stone J,et al.An ultrastructural and systemic analysis of glycosaminoglycans in thyroid-associated ophthalmopathy〔J〕[].Eye.1998
5Kashiwai T,Tada H,Asahi K,et al.Significance of thyroid stimulating antibody and long term follow up in patients with euthyroid Graves’disease〔J〕[].Endocrine Journal.1995
6Kazuo K,Fujikado T,Ohmi G,et al.Value of thyroid stimulating antibody in the diagnosis of thyroid associated ophthalmopathy of euthyroid patients〔J〕[].British Journal of Ophthalmology.1997
7Moris S,Yoshikawa N,Horimoto M,et al.Thyroid stimulating antibody in sera of Graves’ophthalmopathy patients as a possible marker for predicting the efficacy of methylprednisolone pulse therapy〔J〕[].Endocrine Journal.1995
8Hotbauer LC,Mhlberg J,Konig A,et al.Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves’ophthalmopathy undergoing orbital radiotherapy〔J〕[].The Journal of Clinical Endocrinology.1997
9Prummel M,Suttorp-Schulten M,Wiersinga W,et al.A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves’ophthalmopathy〔J〕[].Ophthalmology.1993
10Cheng TC,Huang KM,Hsiao YL,et al.Relationships of orbital computed tomographic findings and activity scores to the prognosis of corticosteroid therapy in patients with Graves’ophthalmopathy〔J〕[].Acta Orthopaedica Scandinavica.1997
